© 2022 MJH Life Sciences and Drug Topics. All rights reserved.
© 2022 MJH Life Sciences™ and Drug Topics. All rights reserved.
September 28, 2022
The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.
September 15, 2022
The review focused on Remicade (infliximab) and Enbrel (etanercept). The annualized discontinuation rate was 21% among patients who had undergone nonmedical switching to biosimilars. However, the rates were similar to those found in some separate analyses of patients on reference biologics.
September 13, 2022
Several provisions in the law are designed to protect and foster the biosimilar market. But some representatives of the sector see CMS drug price negotiation as a threat to profit margins.
September 12, 2022
Some companies are using the interchangeability designation as a marketing ploy.
August 26, 2022
Although further studies are needed to confirm the long-term effects, recent studies have shown the infliximab biosimilar to be a safe, effective, and cost reducing treatment for inflammatory bowel diseases.
August 16, 2022
New research should give expectant mothers some peace of mind.
August 03, 2022
Humira may face competition from multiple generics next year, but an octet of other biologics may also see competition this decade.
June 22, 2022
Six are currently on the market and more are in the pipeline.
June 16, 2022
The biosimilar has a list price 40% less than its reference product.
June 15, 2022
Infliximab biosimilars have been available since 2016.